Novo Nordisk has developed an oral formulation of semaglutide, the active ingredient in the injectable Ozempic, offering type 2 diabetes patients an alternative to weekly injections. The pill form addresses a significant barrier to treatment: injection anxiety and the inconvenience of regular shots.
The oral version works identically to its injectable counterpart. Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar and appetite. By activating GLP-1 receptors in the pancreas, the medication stimulates insulin release when blood glucose rises and slows gastric emptying to prevent blood sugar spikes after meals.
Clinical trials demonstrate the pill's efficacy matches injection performance in controlling blood glucose levels. Patients taking the oral formulation achieved comparable reductions in HbA1c, the marker measuring average blood sugar over three months. The medication also produces modest weight loss, a benefit many patients experience.
Adherence improves with oral administration. Injection anxiety affects roughly 20 percent of diabetic patients, according to research from the American Diabetes Association. Weekly pills eliminate needle-related fears while maintaining medication consistency.
The oral pill requires specific dosing instructions. Patients must take it on an empty stomach, at least 30 minutes before food or beverages, because food significantly reduces absorption. This timing requirement demands more discipline than injectable versions but proves manageable for most patients.
Side effects remain consistent with the injection. Nausea, vomiting, and diarrhea occur most frequently during dose escalation. Gastrointestinal symptoms typically subside as the body adjusts. Rare cases of pancreatitis and thyroid concerns warrant monitoring.
Novo Nordisk priced the oral formulation comparably to the injectable, making cost less of a barrier than access